GLP-1 Drugs Linked to Lower Alzheimer's Risk Amid Safety Warnings
Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight loss. A new study finds that people taking GLP-1 medications like Ozempic, Wegovy, and Mounjaro face up to a 12% lower risk of developing Alzheimer's disease.
Researchers at Washington University in St. Louis examined 215,000 U.S. military veterans with diabetes, comparing those using GLP-1 drugs with those on older treatments. The findings show reduced risks for 42 conditions, including psychotic disorders, seizures, and neurocognitive diseases like Alzheimer's and dementia. However, the study also flags higher risks for kidney issues, pancreatitis, and gastrointestinal conditions among GLP-1 users.
These findings emerge as the Biden administration moves forward with Medicare price negotiations for Ozempic and Wegovy. Meanwhile, Bristol-Myers Squibb (BMY) sees potential in its schizophrenia drug, Cobenfy, as a future Alzheimer's treatment.
This article first appeared on GuruFocus.
